Intellia Therapeutics, Inc. – LSE:0JBU.L
Intellia Therapeutics stock price today
Intellia Therapeutics stock price monthly change
Intellia Therapeutics stock price quarterly change
Intellia Therapeutics stock price yearly change
Intellia Therapeutics key metrics
Market Cap | 1.16B |
Enterprise value | N/A |
P/E | N/A |
EV/Sales | N/A |
EV/EBITDA | N/A |
Price/Sales | N/A |
Price/Book | N/A |
PEG ratio | N/A |
EPS | -5.35 |
Revenue | 52.60M |
EBITDA | -512.35M |
Income | -485.50M |
Revenue Q/Q | 129.53% |
Revenue Y/Y | -1.62% |
Profit margin | 0% |
Oper. margin | 0% |
Gross margin | 0% |
EBIT margin | 0% |
EBITDA margin | -973.99% |
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeIntellia Therapeutics stock price history
Intellia Therapeutics stock forecast
Intellia Therapeutics financial statements
| Jun 2023 | 13.59M | -123.68M | -909.82% |
|---|---|---|---|
| Sep 2023 | 11.99M | -122.22M | -1019.21% |
| Dec 2023 | -1.91M | -132.16M | 6894.16% |
| Mar 2024 | 28.93M | -107.43M | -371.3% |
| Sep 2025 | 17.88M | -128.63M | -719.31% |
|---|---|---|---|
| Oct 2025 | 14.89M | -127.56M | -856.48% |
| Dec 2025 | 14.89M | -127.77M | -857.7% |
| Mar 2026 | 31.72M | -110.51M | -348.36% |
Analysts Price target
Financials & Ratios estimates
| Jun 2023 | 1323240000 | 218.35M | 16.5% |
|---|---|---|---|
| Sep 2023 | 1243349000 | 205.93M | 16.56% |
| Dec 2023 | 1300977000 | 250.80M | 19.28% |
| Mar 2024 | 1259589000 | 223.45M | 17.74% |
| Jun 2023 | -90.32M | -34.53M | 2.51M |
|---|---|---|---|
| Sep 2023 | -101.38M | 79.5M | 19.10M |
| Dec 2023 | -93.05M | 45.93M | 106.48M |
| Mar 2024 | -120.66M | 5.90M | 59.99M |
Intellia Therapeutics alternative data
| Aug 2023 | 598 |
|---|---|
| Sep 2023 | 598 |
| Oct 2023 | 598 |
| Nov 2023 | 598 |
| Dec 2023 | 598 |
| Jan 2024 | 598 |
| Feb 2024 | 598 |
| Mar 2024 | 526 |
| Apr 2024 | 526 |
| May 2024 | 526 |
| Jun 2024 | 526 |
| Jul 2024 | 526 |
Intellia Therapeutics other data
| Patent |
|---|
Application Filling date: 2 Oct 2019 Issue date: 13 Jan 2022 |
Application Filling date: 15 Apr 2021 Issue date: 4 Nov 2021 |
Application Filling date: 25 Mar 2021 Issue date: 22 Jul 2021 |
Application Compositions and Methods for Hydroxyacid Oxidase 1 (HAO1) Gene Editing for Treating Primary Hyperoxaluria Type 1 (PH1) Filling date: 29 Jan 2021 Issue date: 3 Jun 2021 |
Application Filling date: 7 Jun 2019 Issue date: 29 Apr 2021 |
Application Filling date: 4 Dec 2020 Issue date: 25 Mar 2021 |
Application Filling date: 21 Mar 2018 Issue date: 11 Mar 2021 |
Application Filling date: 24 Mar 2020 Issue date: 12 Nov 2020 |
Application Filling date: 28 Sep 2018 Issue date: 1 Oct 2020 |
Application Filling date: 18 Oct 2019 Issue date: 17 Sep 2020 |
| Insider | Compensation |
|---|---|
Dr. John M. Leonard (1957) Pres, Chief Executive Officer & Director | $903,790 |
Mr. José E. Rivera (1966) Executive Vice President, Gen. Counsel & Company Sec. | $637,650 |
Dr. Andrew D. Schiermeier (1970) Executive Vice President & Chief Operating Officer | $615,980 |
Mr. Glenn G. Goddard (1971) Executive Vice President & Chief Financial Officer | $541,840 |
| Dr. Laura Sepp-Lorenzino (1961) Executive Vice President & Chief Scientific Officer | $443,790 |
| Mr. Nessan Bermingham Ph.D. Founder & Member of Scientific Advisor Board | |
Dr. Derrick J. Rossi Founder & Member of Scientific Advisor Board | |
Mr. Andrew May Ph.D. Founder and Member of Scientific Advisor Board | |
| Ms. Rachel Haurwitz Ph.D. Co-Founder | |
| Dr. Jennifer A. Doudna Founder & Member of Scientific Advisor Board |
-
What's the price of Intellia Therapeutics stock today?
One share of Intellia Therapeutics stock can currently be purchased for approximately $117.46.
-
When is Intellia Therapeutics's next earnings date?
Unfortunately, Intellia Therapeutics's (0JBU.L) next earnings date is currently unknown.
-
Does Intellia Therapeutics pay dividends?
No, Intellia Therapeutics does not pay dividends.
-
How much money does Intellia Therapeutics make?
Intellia Therapeutics has a market capitalization of 1.16B and it's past years’ income statements indicate that its last revenue has decreased compared to the previous period by 30.4% to 36.28M US dollars.
-
What is Intellia Therapeutics's stock symbol?
Intellia Therapeutics, Inc. is traded on the LSE under the ticker symbol "0JBU.L".
-
What is Intellia Therapeutics's primary industry?
Company operates in the Healthcare sector and Medical - Pharmaceuticals industry.
-
How do i buy shares of Intellia Therapeutics?
Shares of Intellia Therapeutics can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are Intellia Therapeutics's key executives?
Intellia Therapeutics's management team includes the following people:
- Dr. John M. Leonard Pres, Chief Executive Officer & Director(age: 68, pay: $903,790)
- Mr. José E. Rivera Executive Vice President, Gen. Counsel & Company Sec.(age: 59, pay: $637,650)
- Dr. Andrew D. Schiermeier Executive Vice President & Chief Operating Officer(age: 55, pay: $615,980)
- Mr. Glenn G. Goddard Executive Vice President & Chief Financial Officer(age: 54, pay: $541,840)
- Dr. Laura Sepp-Lorenzino Executive Vice President & Chief Scientific Officer(age: 64, pay: $443,790)
- Mr. Nessan Bermingham Ph.D. Founder & Member of Scientific Advisor Board
- Dr. Derrick J. Rossi Founder & Member of Scientific Advisor Board
- Mr. Andrew May Ph.D. Founder and Member of Scientific Advisor Board
- Ms. Rachel Haurwitz Ph.D. Co-Founder
- Dr. Jennifer A. Doudna Founder & Member of Scientific Advisor Board
-
Is Intellia Therapeutics founder-led company?
Yes, Intellia Therapeutics is a company led by its founders Mr. Nessan Bermingham Ph.D., Dr. Derrick J. Rossi, Mr. Andrew May Ph.D., Ms. Rachel Haurwitz Ph.D. and Dr. Jennifer A. Doudna.
-
How many employees does Intellia Therapeutics have?
As Jul 2024, Intellia Therapeutics employs 526 workers.
-
When Intellia Therapeutics went public?
Intellia Therapeutics, Inc. is publicly traded company for more then 7 years since IPO on 29 Jan 2018.
-
What is Intellia Therapeutics's official website?
The official website for Intellia Therapeutics is intelliatx.com.
-
Where are Intellia Therapeutics's headquarters?
Intellia Therapeutics is headquartered at 40 Erie Street, Cambridge, MA.
-
How can i contact Intellia Therapeutics?
Intellia Therapeutics's mailing address is 40 Erie Street, Cambridge, MA and company can be reached via phone at 857 285 6200.
Intellia Therapeutics company profile:
Intellia Therapeutics, Inc.
intelliatx.comLSE
526
Medical - Pharmaceuticals
Healthcare
Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema, as well as other liver-focused programs comprising hemophilia A and hemophilia B, hyperoxaluria Type 1, and alpha-1 antitrypsin deficiency. Its ex vivo pipeline includes NTLA-5001 for the treatment of acute myeloid leukemia; and proprietary programs focused on developing engineered cell therapies to treat various oncological and autoimmune disorders. In addition, it offers tools comprising of Clustered, Regularly Interspaced Short Palindromic Repeats/CRISPR associated 9 (CRISPR/Cas9) system. Intellia Therapeutics, Inc. has license and collaboration agreements with Novartis Institutes for BioMedical Research, Inc. to engineer hematopoietic stem cells for the treatment of sickle cell disease; Regeneron Pharmaceuticals, Inc. to co-develop potential products for the treatment of hemophilia A and hemophilia B; Ospedale San Raffaele; and a strategic collaboration with SparingVision SAS to develop novel genomic medicines utilizing CRISPR/Cas9 technology for the treatment of ocular diseases. The company was formerly known as AZRN, Inc. Intellia Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.
Cambridge, MA 02139
:
ISIN: US45826J1051
:
